NCT05306249 (GALIG-CBD) is a Phase 2 clinical trial of CBD LGP 50 in HIV Seropositivity, sponsored by Centre Hospitalier Régional d'Orléans.

Who is sponsoring NCT05306249?

NCT05306249 is sponsored by Centre Hospitalier Régional d'Orléans.

What drugs are being tested in NCT05306249?

Interventions in NCT05306249: CBD LGP 50, Placebo.

What condition does NCT05306249 study?

NCT05306249 studies HIV Seropositivity.

Is NCT05306249 still recruiting?

NCT05306249 is currently completed. Last updated 3 April 2023.

Last reviewed 2023-04-03 · How we verify

NCT05306249: GALIG-CBD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected Patients

Completed Phase 2 Last updated 3 April 2023

What this trial tests

Phase 2 trial testing CBD LGP 50 in HIV Seropositivity in 80 participants. Completed in 8 February 2023.

Timeline

16 May 2022

Primary endpoint
8 February 2023

8 February 2023

Quick facts

Lead sponsor	Centre Hospitalier Régional d'Orléans
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	80
Start date	16 May 2022
Primary completion	8 February 2023
Estimated completion	8 February 2023
Sites	1 location across France

Drugs / interventions tested

CBD LGP 50 — full drug profile →
Placebo

Conditions studied

HIV Seropositivity — all drugs for HIV Seropositivity →

Sponsor

Centre Hospitalier Régional d'Orléans

Who can join

18 and older, any sex, with HIV Seropositivity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Autophagy and apoptosis are natural cellular mechanisms which consist for the first in a recycling and elimination process of potentially toxic cellular waste, and for the second in a process of cellular suicide when it becomes abnormal and "not" repairable, notably by autophagy. A deficit in autophagic function at the cellular level can lead to chronic inflammation and accelerated cellular senescence. Apoptosis is a beneficial phenomenon because it eliminates abnormal cells that could endanger the organism if it survives (e.g. karyotypic atypia). Uncontrolled, it can be deleterious if apoptosis is hypo or hyperactive.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Limited Impact of Cannabidiol on Health-related Quality of Life of People With Long-term Controlled HIV: A Double-blind, Randomized, Controlled Trial.
Barré T, Couton C, Mourad A, Carrieri P, et al · · 2024 · cited 1× · PMID 39296339 · DOI 10.1093/ofid/ofae492
Safety and Tolerability of Low-Dose Full-Spectrum Cannabidiol in Long-Term Virally Suppressed Adults with HIV: A Randomized Double-Blind Placebo-Controlled Trial.
Couton C, Wanneveich M, De Dieuleveult B, Robin C, et al · · 2026 · PMID 41934259 · DOI 10.1177/25785125261439014

Verify or expand the search:

Other recruiting trials for HIV Seropositivity

Currently open trials in the same condition.

NCT06799650 — Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV · Phase 2 · recruiting
NCT05122026 — Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics · Phase 1, PHASE2 · active not recruiting
NCT05118490 — Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Is · Phase 4 · active not recruiting
NCT05723653 — Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention · NA · recruiting
NCT04832477 — Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US · NA · active not recruiting

Other Centre Hospitalier Régional d'Orléans trials

Trials by the same sponsor.

NCT07522307 — Psychological Impact of an 80-km Ultra-Endurance Race · recruiting
NCT07522333 — Psychological Impact of an 120-km Ultra-Endurance Race · recruiting
NCT07334964 — Ultrasound-Guided Carpal Tunnel Infiltration: Comparison Between the Manual Method and a Robot-Assisted Method · NA · recruiting
NCT07203807 — Study of the Optimal Number of Repetitions to Investigate the Cerebral Activity by fNIRS During a Voluntary Movement and · completed
NCT07305701 — Cohort Study on Medical Students' Mental Health · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05306249 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Régional d'Orléans
Last refreshed: 3 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05306249.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing